
|Videos|July 18, 2018
Efficacy of Nivolumab in Patients With Melanoma
Author(s)Paolo A. Ascierto, MD
Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.
Advertisement
Paolo A. Ascierto, MD, National Tumour Institute “Fondazione G. Pascale,” Unit of Melanoma in Naples, Italy, discusses the promising results for nivolumab (Opdivo) in patients with melanoma.
According to Ascierto, this agent has proven to be safe and efficacious in this patient population. The incidence of grade 3/4 adverse events (AEs) is also low.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5










































